Imo the solution to get AHZ out of this tight spit is very simple; assuming the break even point is $40m revenue and they continue to grow at 20% Q on Q and flat growth for infusion 2018 fy total will be approximately $28m.
At the same growth rate which is is very conservative fy 2019 should total approx $40m. This does not include any additional products, increased growth or additional infusion revenue.
So the current figures are not that stark.
Anyone could write a business case to attract equity, finance on these figures with a well proven product track record and pipeline. I have written business cases for approval of funds for returns with much less potential and of quantities sonar to what is required to keep AHZ a going concern. Surely our COD can achieve this, it is not a high risk venture if it is presented correctly.
This is not as big a problem as it appears and requires some carefully planning and genuine effort.
TOP post!
Rational and credible.
Ann: Appendix 4C - quarterly, page-265
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.30 |
Change
0.150(0.99%) |
Mkt cap ! $323.4M | |||
| Open | High | Low | Value | Volume |
| $15.35 | $15.35 | $15.00 | $92.29K | 6.09K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50 | $15.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.30 | 276 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |